🇺🇸 FDA
Patent

US 10314904

Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 10314904 (Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/55